As cell and gene therapies move earlier in the disease course and into broader patient populations, the Market Access question is changing. Manufacturers must now ask not only whether a therapy will be covered, but whether that coverage will translate into timely treatment initiation for eligible patients.
In this white paper, Julia Wermerskirchen, PharmD, examines how access risk is shifting downstream, from the coverage decision to the steps that follow. The paper looks at the growing influence of employers, benefit consultants, and emerging management models. It also shows where eligible patients may encounter friction between approval and treatment.
WHAT YOU’LL LEARN:
- How broader eligibility changes the access landscape for cell and gene therapies
- Why employers and plan sponsors are becoming more influential in access decisions
- Top three future priorities for commercialization teams
Download the white paper to learn where patients may encounter friction after coverage approval, and how to strengthen pull-through, launch execution, and sustained access.
